Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
Daniele Generali(University of Trieste), Stephen B. Fox(Peter MacCallum Cancer Centre), Mauro Papotti(University of Turin), Alessandra Bersiga(Istituti Ospitalieri di Cremona), Giovanni Allevi(Istituti Ospitalieri di Cremona), Maria Pia Brizzi(Ospedale San Luigi Gonzaga), Sergio Aguggini(Istituti Ospitalieri di Cremona), Francesca M. Buffa(University of Oxford), Luigi Dogliotti(Aarhus University Hospital), Adrian L. Harris(University of Oxford), Manuela Milani(Humanitas University), Simone Bonardi(Istituti Ospitalieri di Cremona), Alfredo Berruti(Surgical Specialties (Canada)), Leticia Campo(University of Oxford), Alberto Bottini(University of Genoa)
Cited by 116
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k